Antiplatelet agents

[A] STEMI -ASA as soon as possible at a LD of 150–325 mg, followed by 75–100 mg/day. -Ticagrelor (LD of 180 mg, followed by 90 mg × 2/day). -In case of thrombolysis, very high bleeding risk, contraindications to or unavailability of ticagrelor:clopidogrel (LD of 300 mg, followed by 75 mg/day).

[B] NSTEMI -ASA as soon as possible at a LD of 150–325 mg, followed by 75–100 mg/day. -Ticagrelor (LD of 180 mg, followed by 90 mg × 2/day. -In case of very high bleeding risk, contraindications to or unavailability of ticagrelor, it is reasonable to use clopidogrel (LD of 300 mg, followed by 75 mg/day).

Anticoagulant agents

[A] STEMI -Enoxaparin: 30 mg intravenous, followed by 1 mg/kg × 2/day subcutaneously (max 100 mg for the first 2 doses). In patients ≥75 years: no bolus, 0.75 mg/kg × 2/day subcutaneously (max 75 mg for the first 2 doses).

[B] NSTEMI -It is recommended to use fondaparinux (2.5 mg/day subcutaneously). -In case of contraindications to or unavailability of fondaparinux, it is reasonable to use enoxaparin (1 mg/kg × 2/day subcutaneously). -Anticoagulation should be maintained up to hospital discharge. -Crossover of heparins (UFH and LMWH) is not recommended.